Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service hysterectomy, hysteroscopy & ablation cases in Nevada: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (238 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 7 | 583 | 42% |
| 2020 | 4 | 438 | 45% |
| 2021 | 7 | 526 | 48% |
Laparoscopic/robotic hysterectomy, hysteroscopic resection, endometrial ablation. Professional codes (what the surgeon bills): CPT 58571, 58573, 58558, 58563, 58353, 58356, 58661, 58662.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Nevada; 2 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 85 | 6,904+1.6%/yr | +1.6%/yr | 2.3 | 25% | 7,960 in 2030+2.4%/yr |
| Arizona | 21 | 1,973 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Kidney stone management | 26 | 1,008−3.9%/yr | −3.9%/yr | 3.51.0× | 24% | 1,080 in 2030+1.2%/yr |
| BPH procedures |
Hysterectomy, hysteroscopy & ablation in every state, and its device makers · Every procedure market in Nevada · Every state · Compare with California
| 2024 |
| 560 |
| 56% |
| 2025 est. | ≈ 540 | – |
| 2026 est. | ≈ 560 | – |
| 2022 | 2 | 436 | 51% |
| 2023 | 6 | 479 | 54% |
| 2024 | 3 | 560 | 56% |
| 2025 from claims | – | 544 440–639 | 57% |
| 2026 forecast | – | 559 438–702 | 57% |
| 2027 forecast | – | 572 424–756 | 58% |
| 2028 forecast | – | 585 414–807 | 58% |
| 2029 forecast | – | 597 406–857 | 59% |
| 2030 forecast | – | 611 400–906 | 60% |
In 2025, 4% inpatient hospital, 76% hospital outpatient, 7% surgery center, 13% office. The share outside the hospital has moved −3 pts since 2019.
| +0.3%/yr |
| 2.9 |
| 22% |
| 2,360 in 2030+3%/yr |
| Washington | 21 | 1,715−1.7%/yr | −1.7%/yr | 2.4 | 4% | 2,300 in 2030+5%/yr |
| Colorado | 11 | 1,230+1.8%/yr | +1.8%/yr | 2.8 | 8% | 1,580 in 2030+4.2%/yr |
| Oregon | 10 | 1,031+0.7%/yr | +0.7%/yr | 2.7 | 14% | 1,100 in 2030+1.1%/yr |
| Idaho | 5 | 440+2.5%/yr | +2.5%/yr | 2.4 | 9% | 690 in 2030+7.8%/yr |
| New Mexico | 5 | 427−0.8%/yr | −0.8%/yr | 2.0 | 16% | 400 in 2030−1.2%/yr |
| Montana | 7 | 426+5.8%/yr | +5.8%/yr | 2.4 | 8% | 720 in 2030+9.1%/yr |
| Utah | 2 | 384−2.1%/yr | −2.1%/yr | 1.9 | 11% | 380 in 2030−0.1%/yr |
| Alaska | 2 | 275+7.4%/yr | +7.4%/yr | 2.3 | 26% | 220 in 2030−3.5%/yr |
| Hawaii | 2 | 214+5.1%/yr | +5.1%/yr | 1.9 | 14% | 220 in 2030+0.1%/yr |
| Wyoming | 0 | 120+2.1%/yr | +2.1%/yr | 1.1 | 20% | 140 in 2030+2.6%/yr |
| 22 |
| 901−13%/yr |
| −13%/yr |
| 3.10.7× |
| 60% |
| 1,050 in 2030+2.5%/yr |
| Incontinence, prolapse & sacral neuromodulation | 8 | 631−0.3%/yr | −0.3%/yr | 2.21.2× | 19% | 1,080 in 2030+9.3%/yr |
| Prostatectomy & nephrectomy | 4 | 227−1.5%/yr | −1.5%/yr | 0.90.7× | 0% | 510 in 2030+14%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Hologic Sales And Service leads with 92% of company spending on these surgeons in 2025, +42 pts on 2024.
In 2025, 4 companies reported engagement with Nevada’s surgeons worth $19K in consulting, speaking, meals and travel tied to these products, about $6,198 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.